Physician profile
Connie E Roe
NPI 1578912085
$1,198.74
in general payments reported to CMS, 2019-2025
17 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $238 · 2023: $40.28 · 2024: $209 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $180.73 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $155.01 | 2021-2024 | |
| Amgen INC. | $148.08 | 2021-2024 | Tavneos |
| Daiichi Sankyo INC. | $89.95 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $84.62 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $82.98 | 2021-2025 | Farxiga |
| Vifor Pharma, INC. | $78.94 | 2021-2022 | |
| Akebia Therapeutics INC | $77.41 | 2021-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $62.31 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.04 | 2021-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $38.06 | 2021 | |
| Fresenius USA Marketing, INC. | $36.56 | 2021-2023 | Velphoro |
| Travere Therapeutics, INC. | $35.30 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $26.07 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.60 | 2024 | Monoferric |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $14.34 | 2025 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.